clarithromycin + ethambutol + isoniazid + levofloxacin + rifampicin

This is a combination regimen consisting of five antibiotics—clarithromycin, ethambutol, isoniazid, levofloxacin, and rifampicin—used primarily for the treatment of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) and nontuberculous mycobacterial infections. Each component has a distinct mechanism of action targeting different aspects of mycobacterial physiology:

• Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
• Ethambutol interferes with cell wall biosynthesis by inhibiting arabinosyl transferases involved in the polymerization of arabinogalactan.
• Isoniazid inhibits synthesis of mycolic acids essential for the mycobacterial cell wall.
• Levofloxacin is a fluoroquinolone that inhibits DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication.
• Rifampicin binds to the beta subunit of DNA-dependent RNA polymerase, suppressing RNA synthesis.

This multi-drug approach aims to prevent resistance development and achieve synergistic bactericidal activity against resistant strains. The regimen may be used in cases where standard therapy fails or resistance patterns necessitate broader coverage.